SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
This Quarter Return
-13.64%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$410M
AUM Growth
+$410M
(-18%)
Cap. Flow
+$2.14M
Cap. Flow
% of AUM
0.52%
Top 10 Holdings %
Top 10 Hldgs %
98.99%
Holding
11
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
KALA BIO
KALA
|
$1.08M |
| 2 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$1.07M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $180M | 43.88% |
2,346,630
| – | – |
|
2
ARS Pharmaceuticals
SPRY
$1.15B
| $42.3M | 10.32% |
4,012,903
| – | – |
|
3
CRISPR Therapeutics
CRSP
$4.71B
| $41.3M | 10.07% |
1,048,951
| – | – |
|
4
Design Therapeutics
DSGN
$315M
| $40.3M | 9.82% |
6,526,476
| – | – |
|
|
ZBIO
5
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $40.2M | 9.81% |
4,911,539
| – | – |
|
6
Mineralys Therapeutics
MLYS
$1.03B
| $24.8M | 6.05% |
2,016,822
| – | – |
|
|
ALMS
7
Alumis Inc. Common Stock
ALMS
$479M
| $15.4M | 3.76% |
1,959,896
| – | – |
|
|
ORKA
8
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $8.34M | 2.03% |
430,330
+55,000
| +15% | +$1.07M |
|
9
Nkarta
NKTX
$151M
| $8.3M | 2.02% |
3,333,333
| – | – |
|
10
enGene Holdings
ENGN
$236M
| $4.97M | 1.21% |
747,750
| – | – |
|
|
11
KALA BIO
KALA
$78.8M
| $4.16M | 1.01% |
598,940
+155,279
| +35% | +$1.08M |
|